{"schema_version":"secwatch.filing_event.v1","accession":"0001447362-21-000250","form_type":"8-K","ticker":"CSTL","cik":"0001447362","company_name":"CASTLE BIOSCIENCES INC","filed_at":"2021-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.616345+00:00","generated_at":"2026-06-28T11:24:13.174824+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Castle Q3 revenue $23.5M (+54% YoY); guides FY21 $89-93M; acquiring Cernostics","bullets":["Q3 revenue $23.5M, up 54% vs $15.2M in Q3 2020; adjusted revenue $23.6M, up 71%.","Total test reports 7,727 (vs 4,779); DecisionDx-Melanoma 5,505 (+25%), DecisionDx-SCC 934.","Gross margin 77.9%; adjusted 80.9%; cash $363M as of Sept 30, 2021.","Signed definitive agreement to acquire Cernostics (TissueCypher BE test) to expand TAM by ~$1B; close expected by year-end 2021.","On track to meet raised FY21 revenue guidance of $89-93M."],"urls":{"canonical":"https://secwatch.observer/filing/0001447362-21-000250","json":"https://secwatch.observer/filing/0001447362-21-000250.json","markdown":"https://secwatch.observer/filing/0001447362-21-000250.md","text":"https://secwatch.observer/filing/0001447362-21-000250.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447362/000144736221000250/0001447362-21-000250-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447362/000144736221000250/cstl-20211108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T11:24:13.174824+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}